Hims Hers Health is trading 10.7% down at $29.23 as traders lock in gains after a sharp multi-week rally and position cautiously ahead of upcoming regulatory catalysts.
- Investors are reassessing regulatory risks surrounding the company's peptide and metabolic health ambitions ahead of the FDA’s July 23–24 compounding advisory committee meeting.
- The price action is being driven by event-specific uncertainty rather than any new negative company announcements.
- The decline follows a period of significant outperformance, leading to a natural cooling as market participants de-risk before the committee's findings.